Valuation: Beam Therapeutics Inc.

Market Cap 2.45B 2.18B 2.03B 1.85B 3.49B 235B 3.52B 24.57B 9.52B 120B 9.19B 8.99B 386B P/E 2026 *
-5.55x
P/E 2027 * -5.13x
Enterprise Value 1.53B 1.36B 1.27B 1.16B 2.18B 147B 2.2B 15.37B 5.96B 75.28B 5.75B 5.63B 242B EV / Sales 2026 *
31.5x
EV / Sales 2027 * 19.5x
Free-Float
98.75%
Yield 2026 *
-
Yield 2027 * -
1 day+0.45%
1 week+0.95%
Current month+0.20%
1 month-16.35%
3 months-29.58%
6 months-0.65%
Current year-11.62%
1 week 23.44
Extreme 23.44
25.48
1 month 22.67
Extreme 22.67
29.97
Current year 21.63
Extreme 21.63
38.26
1 year 20.23
Extreme 20.23
38.26
3 years 13.52
Extreme 13.525
49.5
5 years 13.52
Extreme 13.525
100.06
10 years 13
Extreme 13
138.52
Manager TitleAgeSince
Chief Executive Officer 48 01/01/2017
Director of Finance/CFO 48 19/12/2024
President 57 24/01/2020
Director TitleAgeSince
Director/Board Member 48 01/01/2017
Director/Board Member 75 01/05/2018
Director/Board Member 56 10/10/2019
Date Insider Type Main position Quantity % Market Cap. Importance
24/09/26 Don

Chairperson

-123,407 0.1195%
27/07/26 Sell

Chief Technology Officer

-16,667 0.0162%
30/06/26 Exercice

Chief Executive Officer

75,000 0.0729%
Change 5-day change 1-year change 3-year change Capi.($)
+0.45%+0.95%-4.26%+13.95% 2.45B
+4.16%+3.04%+49.37%+94.17% 74.16B
-3.11%-3.53%+21.92%+74.60% 57.39B
+0.89%-0.63%+4.28%+34.51% 47.64B
+0.36%+0.81%+352.17%+689.61% 44.29B
-0.96%-4.50%+26.36%+33.18% 42.5B
-0.20%-0.77%+3.74%+100.60% 40.71B
-0.54%+2.93%+9.31%+50.41% 30.97B
-2.68%+2.92%+29.63%+19.50% 28.53B
+0.05%-1.64%-7.28%-14.06% 24.34B
Average -0.16%-0.43%+48.52%+109.65% 39.3B
Weighted average by Cap. +0.12%-0.83%+58.37%+129.19%

Financials

2026 *2027 *
Net sales 48.57M 43.16M 40.28M 36.71M 69.24M 4.67B 69.89M 487M 189M 2.39B 182M 178M 7.66B 62.75M 55.75M 52.04M 47.43M 89.45M 6.03B 90.28M 630M 244M 3.08B 236M 230M 9.9B
Net income -462M -410M -383M -349M -658M -44.4B -664M -4.63B -1.8B -22.7B -1.73B -1.7B -72.84B -537M -477M -445M -406M -765M -51.58B -772M -5.38B -2.09B -26.37B -2.01B -1.97B -84.63B
Net Debt -916M -814M -760M -693M -1.31B -88.09B -1.32B -9.2B -3.56B -45.03B -3.44B -3.37B -145B -1.22B -1.09B -1.01B -923M -1.74B -117B -1.76B -12.26B -4.75B -60.04B -4.59B -4.49B -193B
Logo Beam Therapeutics Inc.
Beam Therapeutics Inc. is a biotechnology company developing precision genetic medicines through base editing. The Company's suite of gene editing technologies is anchored by base editing, a technology that is designed to enable precise, predictable and efficient single base changes, at targeted genomic sequences, without making double-stranded breaks in the deoxyribonucleic acid. Its lead programs are focused on sickle cell disease and alpha-1 antitrypsin deficiency, and it is also advancing programs in other genetic diseases. Its primary programs include BEAM-101, Engineered Stem Cell Antibody Paired Evasion (ESCAPE), BEAM-302 and BEAM-301. BEAM-101 is a patient-specific, autologous hematopoietic stem cell (HSC), investigational therapy. ESCAPE is a potentially non-genotoxic approach to HSC transplantation. BEAM-302 is a liver-targeting lipid nanoparticle formulation of base editing reagents designed to offer a one-time treatment to correct the E342K point mutation (PiZZ genotype).
Employees
540
Date Price Change Volume
02/10/26 $24.50 +0.45% 1,498,573
01/10/26 $24.39 -0.25% 1,695,437
30/09/26 $24.45 -0.29% 1,559,294
29/09/26 $24.52 +1.20% 1,637,524
28/09/26 $24.23 -0.16% 1,274,361
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
15
Last Close Price
24.50USD
Average target price
52.15USD
Spread / Average Target
+112.87%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. BEAM Stock